<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00248443</url>
  </required_header>
  <id_info>
    <org_study_id>P040424</org_study_id>
    <nct_id>NCT00248443</nct_id>
  </id_info>
  <brief_title>Réa-MiniMax: Severe Acute Respiratory Failure in Hematology and Cancer Patients Without Bronchoalveolar Lavage</brief_title>
  <official_title>Severe Acute Respiratory Failure in Hematology and Cancer Patients Without Bronchoalveolar Lavage. A Multicentric Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MiniMax® study is a multicenter randomized controlled study aimed at demonstrating that a&#xD;
      combination of non-invasive diagnostic tools are as effective as fiberoptic bronchoscopy and&#xD;
      bronchoalveolar lavage (FO-BAL) in performing the etiological diagnosis of acute respiratory&#xD;
      failure in cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute respiratory failure is a dreadful complication in cancer patients. Indeed, about 20% of&#xD;
      the patients will present with pulmonary infiltrates, but Intensive Care Unit (ICU) admission&#xD;
      and mechanical ventilation will be needed in half of them resulting in mortality for most of&#xD;
      the patients. Managing cancer patients with respiratory failure implicates three mandatory&#xD;
      tasks: 1) early antibiotics administration covering suspected pathogens; 2) search for the&#xD;
      actual aetiology; and 3) adequate supportive care with access to invasive or non invasive&#xD;
      respiratory support. Performing the etiological diagnosis is crucial. Fiberoptic bronchoscopy&#xD;
      and bronchoalveolar lavage (FO-BAL) remains the cornerstone of the management of pulmonary&#xD;
      infiltrates in cancer patients. However, non-invasive diagnostic tools have been validated in&#xD;
      the recent years. Diagnostic and therapeutic impacts of FO-BAL are only of 30% to 60% and 15%&#xD;
      to 60% respectively. In neutropenic patients and recipients of bone marrow or stem cell&#xD;
      transplantation, this impact is significantly altered. Moreover, reports have highlighted&#xD;
      significant rates of complications such as haemorrhage (5%), respiratory deterioration (11%&#xD;
      to 40%), possibly heading to intubation and subsequent death. Therefore, balancing advantages&#xD;
      to risks of FO-BAL is in order. The MiniMax® study is a multicenter randomized controlled&#xD;
      study aimed at demonstrating that a combination of non-invasive diagnostic tools are as&#xD;
      effective as FO-BAL in performing the etiological diagnosis of acute respiratory failure in&#xD;
      cancer patients. In addition, these non-invasive tests might not lead to deterioration of the&#xD;
      respiratory status and corresponding requirement to intubation and mechanical ventilation.&#xD;
      The group of investigators is used to manage cancer patients with pulmonary involvement. In&#xD;
      the 21 centres, patients will be randomized to be managed either with FO-BAL or with only&#xD;
      non-invasive tools. In each case, patients will be managed with the best supportive care&#xD;
      including adequate antibiotics, respiratory support and all needed life sustaining therapies.&#xD;
      Our hypothesis is to reduce intubation rate using a non-invasive approach (without FO-LBA).&#xD;
      Surrogate markers will be hospital mortality and the number of diagnostic procedures in each&#xD;
      group of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in intubation rate</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at 28 days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation (invasive or non invasive)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological aftereffects</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">206</enrollment>
  <condition>Lymphoma</condition>
  <condition>Cancer</condition>
  <condition>Acute Respiratory Failure</condition>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fiberoptic bronchoscopy and bronchoalveolar lavage</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a malignant haemopathy or a cancer&#xD;
&#xD;
          -  Patients with severe acute respiratory failure requiring admission to an ICU&#xD;
&#xD;
          -  No argument for a congestive cardiac insufficiency (heart failure)&#xD;
&#xD;
          -  Patients who provided their informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18&#xD;
&#xD;
          -  Patient who refuses to undergo fiberoptic bronchoscopy&#xD;
&#xD;
          -  Therapeutic limitation&#xD;
&#xD;
          -  Patients intubated at ICU admission&#xD;
&#xD;
          -  Etiological diagnosis of the acute respiratory failure known&#xD;
&#xD;
          -  Lack of available bronchoscopy&#xD;
&#xD;
          -  AIDS&#xD;
&#xD;
          -  Post-operative direct admission&#xD;
&#xD;
          -  Inclusion in another research protocol in the ICU (HURRIET law)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elie Azoulay, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Réanimation Médicale de l'Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Dunagan DP, Baker AM, Hurd DD, Haponik EF. Bronchoscopic evaluation of pulmonary infiltrates following bone marrow transplantation. Chest. 1997 Jan;111(1):135-41.</citation>
    <PMID>8996007</PMID>
  </reference>
  <reference>
    <citation>White P, Bonacum JT, Miller CB. Utility of fiberoptic bronchoscopy in bone marrow transplant patients. Bone Marrow Transplant. 1997 Oct;20(8):681-7.</citation>
    <PMID>9383232</PMID>
  </reference>
  <reference>
    <citation>Murray PV, O'Brien ME, Padhani AR, Powles R, Cunningham D, Jeanes A, Ashley S. Use of first line bronchoalveolar lavage in the immunosuppressed oncology patient. Bone Marrow Transplant. 2001 May;27(9):967-71.</citation>
    <PMID>11436107</PMID>
  </reference>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>November 3, 2005</study_first_submitted>
  <study_first_submitted_qc>November 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2005</study_first_posted>
  <last_update_submitted>February 17, 2011</last_update_submitted>
  <last_update_submitted_qc>February 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Saliha DJANE</name_title>
    <organization>Department of Clinical Research of developpement</organization>
  </responsible_party>
  <keyword>Haematology and cancer patients</keyword>
  <keyword>Acute respiratory failure</keyword>
  <keyword>Bronchoalveolar lavage</keyword>
  <keyword>Non invasive diagnostic tools</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Intensive Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

